Open AccessRecent Advances in Adenovirus-Vectored Vaccines Development
Author(s) -
Alexander N. Zakhartchouk,
AUTHOR_ID
Publication year - 2017
Publication title -
vaccination research
Language(s) - English
Resource type - Journals
ISSN - 2771-750X
DOI - 10.17140/vroj-2-e004
Subject(s) - virology , clinical trial , medicine , serotype , human immunodeficiency virus (hiv) , neutralizing antibody , vaccine trial , antibody , immunology , virus
Recombinant adenovirus-vectored vaccines based on human adenovirus serotype 5 (HAdV-5) have been extensively studied both pre-clinically and in clinical trials for the past 25 years. Initially, they were considered as the most promising platform for human immunodeficiency virus (HIV) vaccine development. However, HAdV-5-based vaccine did not meet expectations in a large-scale clinical trial called STEP trial. In that trial, the vaccine not only showed lack of efficacy, but also suggested an increased trend for HIV acquisition in individuals with pre-existing HAdV-5 neutralizing antibodies.